Results 191 to 200 of about 103,512 (241)

Regulation of Chondrocyte Metabolism and Osteoarthritis Development by Sirt5 Through Protein Lysine Malonylation

open access: yesArthritis &Rheumatology, EarlyView.
Objective Chondrocytemetabolic dysfunction plays an important role in osteoarthritis (OA) development during aging and obesity. Protein posttranslational modifications (PTMs) have recently emerged as an important regulator of cellular metabolism. We aim to study one type of PTM, lysine malonylation (MaK), and its regulator sirtuin 5 (Sirt5) in OA ...
Huanhuan Liu   +11 more
wiley   +1 more source

Application of a Feedback Journal Club

open access: yesChinese Medical Journal, 2017
Nan-Ze Yu   +11 more
doaj   +1 more source

Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis

open access: yesArthritis &Rheumatology, EarlyView.
Osteoporosis is a chronic disease, and antiresorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used antiresorptive treatments, bisphosphonates and denosumab, have short‐ and long‐term risks that, coupled with their benefits and other unique characteristics, influence ...
Giovanni Adami, Kenneth G. Saag
wiley   +1 more source

Literature review on neonatal pain - OBJN club journal [PDF]

open access: bronze, 2004
Flávia Rocha   +1 more
openalex   +1 more source

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

open access: yesArthritis &Rheumatology, EarlyView.
Objective Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease‐modifying antirheumatic drugs with other modes of action (bDMARD‐OMA) in a multicountry, real‐world population ...
Romain Aymon   +28 more
wiley   +1 more source

Aberrant Glycosylation of IgG in Children With Active Lupus Nephritis Alters Podocyte Metabolism and Causes Podocyte Injury

open access: yesArthritis &Rheumatology, EarlyView.
Objective Podocytes are integral to the maintenance of the glomerular filtration barrier. Their injury results in proteinuria and disease progression in lupus nephritis (LN). Aberrant IgG glycosylation drives podocyte injury in LN and leads to cytoskeletal rearrangement, motility changes, and decreased nephrin production.
Rhea Bhargava   +9 more
wiley   +1 more source

Effect of long‐term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies

open access: yesArthritis &Rheumatology, Accepted Article.
Objective This study characterized the impact of voclosporin on kidney histology in patients with lupus nephritis (LN) who had protocolized repeat kidney biopsies in the AURORA clinical trials. Methods Patients were randomized to voclosporin or placebo treatment for up to three years; all patients received mycophenolate mofetil and low‐dose ...
Brad H. Rovin   +9 more
wiley   +1 more source

Innate Lymphoid Cell Phenotypic and Functional Alterations in Patients With Systemic Juvenile Idiopathic Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic juvenile idiopathic arthritis (sJIA) is a chronic childhood disease classically attributed to innate immune cell dysregulation. This study aimed to elucidate the role of innate lymphoid cells (ILCs), including natural killer (NK) cells and helper‐ILCs (hILCs), in sJIA during clinically inactive disease (CID) through phenotypic and ...
Linda Quatrini   +19 more
wiley   +1 more source

Maintenance of remission after tocilizumab withdrawal in patients with glucocorticoid‐dependent polymyalgia rheumatica

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The SEMAPHORE trial evaluated the efficacy and safety of tocilizumab (TCZ) in glucocorticoid (GC)‐dependent polymyalgia rheumatica (PMR). TCZ reduced GC use and disease activity at 24 weeks. This study aimed to assess relapse rates after stopping TCZ in patients achieving remission at week 24.
Baptiste Chevet   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy